Logo
PFE logo
Pfizer Inc.
PFE
25.53 (0.00%) 0.00
144.68(B)
Health Care
Pharmaceuticals
Pfizer Inc. discovers develops manufactures markets distributes and sells biopharmaceutical products in the United States Europe and internationally. The company offers medicines and vaccines in various therapeutic areas including cardiovascular metabolic migraine and women’s health under the Eliquis Nurtec ODT/Vydura Zavzpret and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family Abrysvo Nimenrix FSME/IMMUN-TicoVac and Trumenba brands; and COVID-19 prevention and treatment and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz Enbrel Inflectra Litfulo Velsipity and Cibinqo brands; amyloidosis hemophilia endocrine diseases and sickle cell disease under the Vyndaqel family Oxbryta BeneFIX Somavert Ngenla and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon Medrol Zavicefta Zithromax and Panzyga brands; and biologics small molecules immunotherapies and biosimilars under the Ibrance Xtandi Inlyta Bosulif Mektovi Padcev Adcetris Talzenna Tukysa Elrexfio Tivdak Lorbrena and Braftovi brands. In addition the company involved in the contract manufacturing business. It serves wholesalers retailers hospitals clinics government agencies pharmacies individual provider offices retail pharmacies and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US Inc.; Merck KGaA; and BioNTech SE as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York New York.
Holdings:
Shares:
Cost basis:

Pfizer Inc. (PFE) price target and intrinsic value estimate

PFE's fair price estimate is $35.7

This valuation is based on a fair P/E of 12.8 and EPS estimates of $2.80

The median analyst price target for PFE is $30.5.

Analyst price targets range from $25.0 to $42.0

Is PFE overvalued or undervalued?

PFE is currently trading at $25.53

PFE is undervalued by 29% using the pevaluation method.

PFE is undervalued by 16% compared to median analyst price targets.

Do you agree with this valuation?

Valuation

PEvaluation

Current price
$25.53
Undervalued
Low
$26.8
Median
$35.7
High
$44.7
Fair P/E
Margin of safety

Analyst valuation

Current price
$25.53
Fairly valued
Low
$25.0
Median
$30.5
High
$42.0
Strong Buy3
Buy7
Hold13
Sell1
Strong Sell0

Discounted cash-flow

N/A
Negative FCF or FCF estimates
TTM FCFFCF est.Growth FCFTerminal FCF
Discount
rate
10%
Terminal
rate
5%
Growth p.
length
5y
Growth p.
rate
10%
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: Wide
None/narrowMediumWideVery wide

Overview

Market data

Market cap:$144.68(B)
Enterprise value:$202.94(B)
Total Equity:$92.56(B)
Shares outstanding:5.67(B)
Div. yield:6.58%
P/S:2.27
P/E:17.98
P/FCF:N/A
P/B:1.57
EPS:$1.4
FCF per share:$0.0
Dividend per share:$1.7

Income (TTM)

RevenueGrossNet
Revenue$63.63(B)
Gross profit$47.21(B)
EBITDA$23.27(B)
Net income$8.03(B)
Gross margin74.2%
Net margin12.6%

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$0
Total liabilities$0
Cash & Short-term inv.$9.95(B)
Long-term debt$0
Debt issued$0
Debt repaid$0

Cash flow (TTM)

CFOCFICFF
FCF$0
CapEx$0
Dividends paid$0
Stock issued$0
Stock repurchased$0
Stock-based comp.$0

Future Growth

Revenue

CAGR: -2.3%
FY+1FY+2FY+3FY+4FY+5
FY+1$63.00(B)
FY+2$63.21(B)
FY+3$62.24(B)
FY+4$60.26(B)
FY+5$57.38(B)

Net Income

CAGR: -1.7%
FY+1FY+2FY+3FY+4FY+5
FY+1$16.94(B)
FY+2$17.52(B)
FY+3$17.53(B)
FY+4$16.75(B)
FY+5$15.82(B)

EPS

CAGR: -2.2%
FY+1FY+2FY+3FY+4FY+5
FY+1$2.95
FY+2$3.06
FY+3$3.05
FY+4$2.89
FY+5$2.70

FCF per share

CAGR: 11.1%
FY+1FY+2
FY+1$2.70
FY+2$3.00

Similar Companies

Historical Financials

Showing limited histrical data. Access 10+ years of financials now! Upgrade
YearlyQuarterly
Income
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
RevenueNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AOperating IncomeInterest ExpenseInterest IncomePre-tax incomeIncome tax
Cash flow
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
FCFCFONet IncomeD&AStock-based Comp.CFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Shares outstanding
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Shares (Basic)Shares (Diluted)
Per share data
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
EPS (Basic)EPS (Diluted)FCF/ShareDividend/ShareBook value/Share
Ratios
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
P/EP/FCFP/BP/SEV/EarningsEV/FCFDebt/EquityPayout ratio
Margins
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin
Returns
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
ROICROAROCEROE
Market Cap.
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Market Cap.